
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

**June 20, 2007
Date of Report (Date of earliest event reported)**

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

000-50614
(Commission File Number)

59-3410522
(IRS Employer
Identification No.)

**13700 Progress Boulevard
Alachua, Florida 32615**
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

Dr. Ronald P. Evens was appointed to the Board of Directors of Orogenics, Inc. as an independent director effective June 15, 2007, filling the vacancy created by the resignation of George Hawes in May 2007. Dr. Evens was also appointed to the Board's Audit Committee. As a result of his appointments, at least fifty percent of the Company's Board is comprised of independent directors and it maintains an Audit Committee of at least two independent directors as required by AMEX's continued listing standards, specifically Sections 802, 803 and 121B(2)(c) of the AMEX Guide. Consistent with Company's revised compensation arrangements for Board services, Dr. Evens received an initial one time grant of stock options to acquire 65,000 shares of common stock under the Company Stock Incentive Plan in lieu of any future meeting fees.

A copy of the press release issued by the Company on June 18, 2007 is attached as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated June 18, 2007 announcing appointment of Dr. Ronald P. Evens as an independent director.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 20, 2007

ORAGENICS, INC.
(Registrant)

BY: /s/ Robert T. Zahradnik
Robert T. Zahradnik
President and Chief Executive Officer

Orogenics Appoints Dr. Ronald P. Evens to its Board of Directors**FOR IMMEDIATE RELEASE**

ALACHUA, FL (June 18, 2007) – Orogenics, Inc. (AMEX:ONT), a biotechnology development company, announced today that Dr. Ronald Evens has been appointed to the Company's Board of Directors. "Dr. Evens has a tremendous depth of pharmaceutical industry experience and we anticipate he will contribute significantly to the growth of Orogenics. We are very pleased to welcome Ron to our Board," said David Gury, Chairman of Orogenics.

Dr. Ron Evens is currently President and CEO of MAPS 4 Biotech, a biotechnology consulting company in Jacksonville, Florida, and is Clinical Professor, University of Florida, College of Pharmacy. Prior to that, Dr. Evens has had a distinguished industrial career, including thirteen years at Amgen, a leading human therapeutics biotechnology company, where he served as Senior Director and Head of Professional Services. Prior to that, he spent six years at Bristol-Myers, a global pharmaceutical company, where he was Associate Director, Clinical Research & Medical Services. He has written/edited the book, "Drug & Biological Development, From Molecule to Product & Beyond" (Springer, 2007), and has served on twelve professional and medical Boards of Directors or Advisory Boards.

Earlier this month, the Company's Board of Directors appointed Dotti Delfino as Chief Financial Officer. Dr. Robert Zahradnik, Orogenics' President and CEO, stated, "Dotti's dedication and contributions to Orogenics are greatly appreciated. We are delighted that she has accepted our offer to serve as an Officer of the Company." Ms. Delfino joined Orogenics in May 2006 as the Corporate Controller, and before that time she held positions of increasing financial responsibility in both industry and academia.

About Orogenics

Orogenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and weight loss. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Orogenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking

statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Orogenics, Inc.
Robert T. Zahradnik, 386-418-4018 X222
www.orogenics.com

###